Biogen sees biosimilars as central to safeguarding the future of healthcare innovation. As biologics go off-patent, biosimilars – biologics medicines that are highly similar to an already-approved biologic – can play an important role in expanding access to treatments. They can also provide significant cost savings contributing to future health care sustainability. By offering cost savings, biosimilars can alleviate some of the burden on healthcare systems and promote sustainable access.

But producing biosimilars is not a simple task. It takes extensive experience, state-of-the-art manufacturing facilities, and a commitment to patient access to do so.

Leveraging our manufacturing excellence, we have gained a deep understanding of what it takes to consistently manufacture advanced biologics. And our extensive manufacturing capacity allows us to independently manage and build redundancies within our supply chain, thereby providing confidence that a consistent and reliable supply of medicines will be available for patients, healthcare providers, and payers when and where they need them.